Brief: Wave Life Sciences Highlights Strategic Priorities For 2026 At The 44Th Annual J.P. Morgan Healthcare Conference Accelerating Development Of Wve-007 (Inhbe Sirna) For Obesity And Rapidly Advancing Rna Editing Portfolio

Wave Life Sciences

12/01/2026 12:36

Jan 12 (Reuters) - WAVE Life Sciences Ltd WVE.O:

WAVE LIFE SCIENCES HIGHLIGHTS STRATEGIC PRIORITIES FOR 2026 AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE: ACCELERATING DEVELOPMENT OF WVE-007 (INHBE SIRNA) FOR OBESITY AND RAPIDLY ADVANCING RNA EDITING PORTFOLIO

WAVE LIFE SCIENCES: EXPECTS TO FILE CTA IN 2026 FOR WVE-008 IN U.S. AND EUROPE

WAVE LIFE SCIENCES : REMAINS ON TRACK TO FILE NDA IN 2026 TO SUPPORT ACCELERATED APPROVAL OF WVE-N531 WITH MONTHLY DOSING

Source text: ID:nGNX3BWr4B

Further company coverage: WVE.O

 ((Reuters.Briefs@thomsonreuters.com;))